This phase 3 trial will investigate the effect of bupropion (Wellbutrin) to treat fatigue in patients with breast cancer (BC).
The main outcomes will be fatigue, quality of life and depression. This trial is recruiting across the United States.
After treatment for breast cancer (BC), many women report feeling excessively tired (fatigue). Fatigue can have a negative impact on the quality of life. It is important to treat this symptom in BC survivors. Bupropion is a drug that is usually used to treat depression. It blocks the reuptake of two hormones – norepinephrine and dopamine. It may also help improve fatigue symptoms.
This trial will investigate the effect of bupropion to treat fatigue in BC. The main outcome will be fatigue.
Who are they looking for?
This study will recruit 422 BC survivors. Participants must be BC-free with fatigue due to cancer. Patients must have completed BC treatment more than 12 months previously. Women of child-bearing potential must agree to use adequate contraception during the study.
Women cannot take part if they have another cause of fatigue. Other exclusion criteria include a history of kidney impairment, cirrhosis, seizures, eating disorders, psychiatric or neurological disorders. Patients with an allergy to lactose will also be excluded.
How will it work
Participants will be randomly assigned to one of two groups. One group will be treated with bupropion. The other will be treated with placebo (inactive tablet). The study will last for up to 13 weeks.